Governance Vanda Pharmaceuticals Inc.

VNDA

US9216591084

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-05-12 pm EDT			5-day change	1st Jan Change
6.420 ^USD	+2.39%		-13.13%	-27.21%

May. 07	Vanda Pharmaceuticals Inc., Q1 2026 Earnings Call, May 06, 2026
May. 06	Vanda Pharmaceuticals Inc. Raises Revenue Guidance for the Full-Year 2026	CI

Executive Committee: Vanda Pharmaceuticals Inc.

Manager

Positions heldSince

Mihael Polymeropoulos

66 year

Chief Executive Officer	2003-04-30
Founder	2002-10-31
President	2003-04-30

Kim Wijkstrom

60 year

Sales & Marketing

2019-08-20

Scott Howell

Human Resources Officer

2019-07-31

Kevin Moran

42 year

Director of Finance/CFO	2020-03-14
Investor Relations Contact	2012-11-30
Treasurer	2020-03-14

Composition of the Board of Directors: Vanda Pharmaceuticals Inc.

Director

CommitteesSince

Mihael Polymeropoulos

66 year

Chairman

2021-05-31

Anne Ward

54 year

Audit Committee	2020-02-13
Compensation Committee Chair
Governance Committee Chair	2020-11-05
Nominating Committee Chair	2020-11-05

Tage Honoré

75 year

Compensation Committee	2023-03-14
Governance Committee	2023-03-14
Nominating Committee	2023-03-14

Phaedra Chrousos

46 year

Audit Committee	2019-04-23
Governance Committee Chair
Nominating Committee Chair

Stephen Mitchell

74 year

Governance Committee	2020-02-13
Nominating Committee	2020-02-13

Richard Dugan

84 year

Compensation Committee	2005-11-30
Audit Committee Chair	2005-11-30

Charles Duncan

Director/Board Member	2026-04-21
Independent Dir/Board Member	2026-04-21

Latest Appointments: Vanda Pharmaceuticals Inc.

Apr. 22	Vanda Pharmaceuticals Inc. Appoints Charles Duncan to Its Board of Directors, Effective April 22, 2026	CI
Apr. 13	Geron Corporation Announces Appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary	CI
Apr. 02	Vanda Pharmaceuticals Inc. Announces Resignation of Timothy Williams as Senior Vice President, General Counsel and Secretary, Effective April 10, 2026	CI
23-03-17	Vanda Pharmaceuticals Inc. Appoints Dr. Tage Honoré to its Board of Directors	CI
22-04-25	H. Thomas Watkins Not Stands for Reelection of Vanda Pharmaceuticals Inc	CI
21-10-08	Vanda Pharmaceuticals Inc. Announces Resignation of Aranthan “Aj” Jones II as the Corporate Affairs and Communications Officer	CI
20-04-22	Vanda Pharmaceuticals Inc. Announces Resignation of Mihael H. Polymeropoulos as Director	CI

More news

Former Officers and Directors: Vanda Pharmaceuticals Inc.

Insider

Positions held

SinceUntil

Tim Williams

General Counsel	2018-08-12	2026-04-09
Corporate Secretary	2018-08-12	2026-04-09

Deepak Shripad Phadke

Corporate Officer/Principal

2005-07-31

2025-03-31

H. Watkins

Director/Board Member	2006-09-11	2011-10-31
Chairman	2014-03-30	-
Independent Dir/Board Member	2006-09-11	2022-06-15

Aranthan Jones

Public Communications Contact	2019-08-20	2021-10-25
General Counsel	2019-08-20	2021-10-25

Gian Reverberi

Corporate Officer/Principal

2015-09-07

2020-03-15

James Kelly

Comptroller/Controller/Auditor	-	2018-08-12
Director of Finance/CFO	2010-12-14	2020-03-14
Investor Relations Contact	2010-12-12	2020-03-14
Corporate Secretary	2010-12-14	2018-08-12
Treasurer	2010-12-14	2020-03-14

Michael Cola

Director/Board Member	2012-06-17	2020-02-13
Independent Dir/Board Member	2012-06-17	2020-02-13

Vin Milano Milano

Director/Board Member	2010-04-20	2019-06-12
Independent Dir/Board Member	2010-04-14	2019-06-12

Ken Bate

Director/Board Member	2015-12-16	2018-06-12
Independent Dir/Board Member	2015-12-16	2018-06-12

Richard L. Gulino

General Counsel	2015-09-13	2018-05-01
Corporate Secretary	2015-09-13	2018-05-01

Howard H. Pien

Director/Board Member	2007-06-04	2009-12-31
Chairman	2009-12-31	2015-12-31
Independent Dir/Board Member	2007-06-04	2009-12-31

Thomas Gibbs

Corporate Officer/Principal	2015-04-19	2015-12-16
Corporate Officer/Principal	2015-02-28	2015-11-30

Steven Galson

Director/Board Member	2010-07-01	2015-06-17
Independent Dir/Board Member	2010-06-30	2015-06-17

Philip Herman

Sales & Marketing

2012-12-31

2015-02-28

Joseph A. Sliman

Chief Tech/Sci/R&D Officer

2012-08-31

2013-12-31

Robert Repella

Corporate Officer/Principal

2011-10-25

Argeris Karabelas

Director/Board Member	2011-11-14	2012-01-17
Chairman	2009-11-17	2011-11-14
Founder	2001-12-31	2011-11-14
Independent Dir/Board Member	2011-11-15	2012-01-17

Stephanie R. Irish

Comptroller/Controller/Auditor	2010-08-05	2010-08-05
Director of Finance/CFO	2010-08-05	2010-08-05
Corporate Secretary	2010-08-05	2010-08-05
Treasurer	2010-08-05	2010-08-05

Brian Halak

Director/Board Member

2003-12-31

2010-04-20

Chip Clark

Founder	2001-12-31	2010-03-25
Corporate Secretary	2002-12-31	2010-03-25

David Ramsay

Director/Board Member

2003-12-31

2010-01-06

Frederick H. Graff

Sales & Marketing

2007-12-31

2009-12-31

Steven Shallcross

Director of Finance/CFO	2005-10-31	2009-01-08
Treasurer	2005-10-31	2009-01-08

Paolo Baroldi

Chief Tech/Sci/R&D Officer	2006-06-30	2009-01-08
Chief Tech/Sci/R&D Officer	2013-04-16	2017-03-21

Todd Horich

Sales & Marketing

2005-12-31

2008-12-31

Albert W. Gianchetti

Corporate Officer/Principal

2007-10-24

2008-11-30

Jan Smilek

Director of Finance/CFO

2005-12-31

2008-01-31

John Joseph Feeney

Chief Tech/Sci/R&D Officer

2009-01-08

Thomas Lyle Copmann

General Counsel

2005-03-31

2007-10-23

James Tananbaum

Director/Board Member

2003-12-31

2007-06-04

Wayne T. Hockmeyer

Director/Board Member

2003-12-31

2006-09-11

Ankit Mahadevia

Corporate Officer/Principal

Ashish Khanna

Corporate Officer/Principal

Curt Wolfgang

General Counsel

Heng Tong Choo

Director/Board Member

Christian Lavedan

Corporate Officer/Principal

Mark Leschly

Director/Board Member

Cristina Murphy

Investor Relations Contact	2011-10-25	-
Public Communications Contact	2010-07-04	-

Age distribution of managers

Parity Men Women

Male	9
Female	2

Of which Executive Committee

Male	4
Female	0

Of which Directors

Male	5
Female	2

Revisions

Recommandations analystes

Évolution recommandations analystes 1 an

Évolution recommandations analystes 4 mois

Objectif analystes

Évolution objectif analystes 1 an

Évolution objectif analystes 4 mois

ESG MSCI

Environnement

Social

Gouvernance

Polémique

Controverses Ethiques

Controverses sur les droits de l'Homme

Controverses Subventions fiscales

Conforme à la finance Islamique

Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Companyâ€™s commercial portfolio consist of three products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome (SMS) and PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Tradipitant, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.

Employees

533

Sector

Biotechnology & Medical Research

More about the company